Navigation Links
Synthetic Biologics to Host Irritable Bowel Syndrome (IBS) Investor Day
Date:8/13/2014

ROCKVILLE, Md., Aug. 13, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS). 

Synthetic Biologics' CEO, Jeffery Riley, and Joseph Sliman, M.D., M.P.H., Senior Vice President, Clinical & Regulatory Affairs, will provide an overview of the anticipated clinical and regulatory pathway for SYN-010 to reduce the impact of methane producing organisms on C-IBS, including plans to file an Investigational New Drug (IND) application and initiate a Phase II dose-discovery and proof-of-mechanism clinical study in the second half of 2014. Keynote speaker, Dr. Mark Pimentel will discuss his groundbreaking work that led to the discovery of SYN-010, including the association between the overproduction of methane gas by microorganisms in the gut and conditions such as C-IBS, as well as further detail for SYN-010 itself.

Event Detail:

Tuesday, September 16, 2014
9:00 a.m. to 11:00 a.m. EDT
Grand Hyatt New York Hotel, New York City

This event will be accessible via live webcast, to be made available on Synthetic Biologics' website.

Keynote Speaker Bio:

Dr. Mark Pimentel is Director, GI Motility Program and Laboratory, and Professor of Medicine at Cedars-Sinai Medical Center in Los Angeles, California.  Active in research, Dr. Pimentel has served as a principal investigator or co-investigator for numerous basic science, translational and clinical studies in IBS, and the relationship between gut flora composition and human disease. Dr. Pimentel is the lead investigator for Synthetic Biologics' C-IBS program, as well as the Chairman of the Company's C-IBS Clinical Advisory Board.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases. The Company is developing an oral biologic to protect the gastrointestinal microflora from the effects of IV antibiotics for the prevention of Clostridium difficile (C. difficile) infection, an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS), a series of monoclonal antibodies for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, the Company is developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS. For more information, please visit Synthetic Biologics' website at www.syntheticbiologics.com.

This release includes forward-looking statements on Synthetic Biologics' current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding Synthetic Biologics' plans to file an Investigational New Drug (IND) application and initiate a Phase II dose-discovery and proof-of-mechanism clinical study in the second half of 2014. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics' forward-looking statements include, among others, the IND  filing and clinical trial not being commenced when planned and other factors described in Synthetic Biologics' report on Form 10-K for the year ended December 31, 2013 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

Logo - http://photos.prnewswire.com/prnh/20130522/MM19465LOGO


'/>"/>
SOURCE Synthetic Biologics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Synthetic Biologics, Inc. States that Its Policy is Not to Comment on Unusual Market Activity
2. Synthetic Biologics Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference
3. Synthetic Biologics Webcast Conference Call Set for 9:00 a.m. EST this Morning, December 9th
4. Synthetic Biologics Enters into License with Cedars-Sinai Medical Center to Develop Novel Anti-infective Approaches for Irritable Bowel Syndrome (IBS), Obesity and Diabetes
5. Study Results Reveal Oral Growth Hormone Boosting Supplement May Be Capable of Producing the Same Benefits as Synthetic Growth Hormone Injections
6. Synthetic Biologics to Present at the First Global Life Sciences Conference in Warsaw, Poland
7. Former Pfizer/Wyeth Global Infectious Disease Pharmaceutical Executive, Lewis Barrett, Appointed Senior Vice President, Commercial Strategy of Synthetic Biologics, Inc.
8. New Legal Synthetic Drug Epidemic Sweeps Smoke Shops Among Young Adults
9. Synthetically Optimized HIF-1 Alpha DNA Delivered with Inovios Electroporation Technology Provides Significant Therapeutic Effects for Peripheral Arterial Disease in Animal Model
10. Synthetic Biologics to Host Multiple Sclerosis-Estriol Investor Day in New York City on June 25, 2013
11. Research Team Publishes New Methods for Synthetic Generation of Influenza Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ® ... fulfilling the promise of precision medicine, today announced that ... Caris, Precision Oncology Alliance™ (POA) as its 17 th ... the St. Jude Crosson Cancer Institute will help develop ... use of tumor profiling, making cancer treatment more precise ...
(Date:10/10/2017)... ORANGE COUNTY, Calif. , Oct. 10, 2017  NDS received ... Mobile  — a medical-grade battery-powered display stand specifically designed for ... aims to transform technology into a clinical solution to support the ... costs. Innovative Design ... NDS ZeroWire Mobile Wireless Solution ...
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... nation's first interactive health literacy software tool, and the Cancer Patient Education Network ... cancer patient education, today announce a new strategic alliance. , As CPEN’s ...
(Date:10/12/2017)... D.C. (PRWEB) , ... October 12, 2017 , ... ... Cal Dining at the University of California Berkeley, and other leading institutions in ... the buying power of institutions to change the way animals are raised for ...
Breaking Medicine News(10 mins):